Loading…
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, Mitchell Ponseti, VerteGlideTM, and Boston Brace 3D. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $236M | $-8M | $-40M | $-16M | -11.4% | 15.4% | 4.8% |
| 2024 | $205M | $-10M | $-38M | $-41M | -10.7% | 37.6% | 80.3% |
| 2023 | $149M | $-8M | $-21M | $-44M | -5.6% | 21.6% | -1767.2% |
| 2022 | $122M | $-9M | $1M | $-32M | 0.3% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 122.29 | 148.73 | 204.73 | 236.35 |
| Operating Revenue | - | 122.29 | 148.73 | 204.73 | 236.35 |
| Cost Of Revenue | - | 31.63 | 37.48 | 56.13 | 63.69 |
| Gross Profit | - | 90.66 | 111.25 | 148.60 | 172.66 |
| Operating Expense | - | 112.45 | 137.02 | 178.12 | 201.66 |
| Research And Development | - | 8.45 | 10.90 | 11.03 | 9.10 |
| Selling General And Administration | - | 104 | 126.12 | 167.08 | 192.56 |
| Total Expenses | - | 144.08 | 174.50 | 234.25 | 265.35 |
| Operating Income | - | -21.79 | -25.77 | -29.52 | -29 |
| Total Operating Income As Reported | - | -25.40 | -26.75 | -35.01 | -39.24 |
| EBITDA | - | -8.69 | -8.38 | -10.44 | -7.88 |
| Normalized EBITDA | - | -31.01 | -10.38 | -1.72 | 2.36 |
| EBIT | - | -21.79 | -25.77 | -29.52 | -29 |
| Interest Expense | 2.25 | 2.42 | - | - | - |
| Net Interest Income | - | -2.42 | 0.20 | -2.62 | -6 |
| Other Non Operating Income Expenses | - | -1.80 | 2.26 | -1.07 | 6.05 |
| Other Income Expense | - | 20.52 | 4.26 | -9.79 | -4.19 |
| Interest Expense Non Operating | 2.25 | 2.42 | - | - | - |
| Net Non Operating Interest Income Expense | - | -2.42 | 0.20 | -2.62 | -6 |
| Pretax Income | - | -3.69 | -21.31 | -41.93 | -39.19 |
| Tax Provision | - | -4.95 | -0.34 | -4.11 | 0.46 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 4.69 | 0.03 | -0.85 | -2.15 |
| Net Income Continuous Operations | - | 1.26 | -20.97 | -37.82 | -39.65 |
| Net Income From Continuing And Discontinued Operation | - | 1.26 | -20.97 | -37.82 | -39.65 |
| Net Income From Continuing Operation Net Minority Interest | - | 1.26 | -20.97 | -37.82 | -39.65 |
| Net Income | - | 1.26 | -20.97 | -37.82 | -39.65 |
| Net Income Common Stockholders | - | 1.24 | -20.97 | -37.82 | -39.65 |
| Net Income Including Noncontrolling Interests | - | 1.26 | -20.97 | -37.82 | -39.65 |
| Normalized Income | - | -16.38 | -22.94 | -29.96 | -31.56 |
| Diluted NI Availto Com Stockholders | - | 1.24 | -20.97 | -37.82 | -39.65 |
| Basic Average Shares | - | 20.70 | 22.68 | 23.08 | 23.46 |
| Diluted Average Shares | - | 20.95 | 22.68 | 23.08 | 23.46 |
| Reconciled Depreciation | - | 13.10 | 17.39 | 19.08 | 21.12 |
| Reconciled Cost Of Revenue | - | 31.63 | 37.48 | 56.13 | 63.69 |
| Total Unusual Items | - | 22.32 | 2 | -8.72 | -10.24 |
| Total Unusual Items Excluding Goodwill | - | 22.32 | 2 | -8.72 | -10.24 |
| Net Income Discontinuous Operations | 0 | - | - | - | - |
| Special Income Charges | - | 22.32 | 2 | -8.72 | -10.24 |
| Other Special Charges | 0.15 | - | - | 3.23 | - |
| Impairment Of Capital Assets | - | 3.61 | 0.98 | 1.84 | 4.64 |
| Restructuring And Mergern Acquisition | - | -25.93 | -2.98 | 3.65 | 5.60 |
| General And Administrative Expense | - | 57.90 | 73.30 | 102.79 | 119.83 |
| Other Gand A | - | 57.90 | 73.30 | 102.79 | 119.83 |
| Total Other Finance Cost | - | 2.42 | -0.20 | 2.62 | 6 |
| Selling And Marketing Expense | - | 46.09 | 52.82 | 64.30 | 72.73 |
| Otherunder Preferred Stock Dividend | - | 0.02 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| OrthoPediatrics Corp.this co. | KIDS | $465M | -11.73 | 1.34 | -11.4% | -69.20 |
| Prothena Corporation plc | PRTA | $484M | -1.98 | 1.73 | -87.0% | -1.01 |
| The Oncology Institute, Inc. | TOI | $474M | -7.82 | -30.15 | 385.5% | -12.80 |
| CTEV | CTEV | $470M | - | - | 163.5% | 10.85 |
| Weave Communications, Inc. | WEAV | $459M | -16.37 |
| - |
| - |
| - |
| - |
| - |
| 5.57 |
| -34.1% |
| -42.33 |
| Editas Medicine, Inc. | EDIT | $459M | -2.87 | 16.82 | -586.6% | -2.22 |
| NRC Health | NRC | $445M | 38.37 | 31.82 | 82.9% | 17.20 |
| Myriad Genetics, Inc. | MYGN | $443M | -1.21 | 1.20 | -99.4% | -1.52 |
| Varex Imaging Corporation | VREX | $441M | - | 0.93 | -14.9% | 973.79 |
| Peer Median | - | -2.43 | 1.73 | -24.5% | -1.26 | |